4BIO Capital
Venture capitalLondon · Pre-Seed–Series B · 25 people tracked
Investment thesis
4BIO Capital targets early-stage companies developing advanced therapies addressing areas of significant unmet medical need, with a focus on cell and gene therapy, RNA-based therapy, targeted therapies, and the microbiome sector. The firm's team brings deep scientific expertise with over 250 combined publications in premier medical journals, coupled with life science investment experience, enabling identification of high-quality investment opportunities with strong scientific and commercial potential.
Source: firm website, verified Jul 21, 2026.
Team · 25 people
from the firm's websiteFormer CEO of Vifor Pharma and former Global President of Pharmaceuticals and Vaccines at GSK.
Professor of Paediatric Immunology at UCL Institute of Child Health and Wellcome Trust Principal Research Fellow.
Chief Scientific Officer at Cancer Research Technology and Board Member at Spirogen.
Professor of Neurology at UCL and Consultant Neurologist at the National Hospital for Neurology and Neurosurgery.
Adjunct Assistant Professor at University of Pennsylvania School of Medicine and Director of the Clinical Vector Core at The Children's Hospital of Philadelphia.
MD, PhD and Professor of Microbiology and Immunology at Keio University School of Medicine, and scientific co-founder of Vedanta Biosciences.
Associate Professor of Translational Vectorology at University of Sydney and co-founder and CTO of LogicBio.
Investment Partner at Hevolution Foundation and former Investment Director and Managing Director at JDRF T1D Fund.
What they invest in
from 1 of 1 portfolio companiesBiotech ×1Medical Devices ×1
Investments · 1 tracked
founders shown can be your intro pathMarch Bioscience is a cell therapy company assembling leading scientists and drug developers to advance cell therapy treatments. The company focuses on developing therapeutics in the cell and gene therapy space.
BiotechMedical Devices
Sarah Hein(CEO, Co-Founder)Maksim Mamonkin(Co-Founder, Chair Scientific Advisory Board)Malcolm Brenner(Co-founder)
Frequently asked questions
- What stage does 4BIO Capital invest at?
- 4BIO Capital invests at the Pre-Seed, Seed, Series A, Series B stages.
- What sectors does 4BIO Capital focus on?
- 4BIO Capital focuses on Biotech, Medical Devices.
- Where is 4BIO Capital located?
- 4BIO Capital is headquartered in London, GB.
Similar investors
B Capital is a venture capital firm managing over $12 billion in assets with a stage-based fund approach. The firm invests across early to late-stage companies in technology, healthcare, and energy & resilience sectors, with 200+ portfolio companies and 9 global offices.
Breyer Capital is a venture capital firm that invests in high-impact entrepreneurs with a strategic focus on companies leveraging artificial intelligence and machine learning to transform technology sectors globally.
DCVC is a deep tech venture capital firm with over a dozen years of experience backing entrepreneurs using computational approaches to solve trillion-dollar problems across industries including AI, climate, materials science, robotics, space, and biology.
Innovestor is a Finnish investment manager that operates across venture capital, real estate, and energy storage sectors. The firm invests in early-stage technology and life science startups, energy-efficient commercial real estate, and battery storage and solar solutions. Innovestor also provides corporate venturing advisory services.
A European investment firm established in 2016 by former Index Ventures life sciences professionals with over 20 years of experience in drug discovery and therapeutic development for unmet medical needs.